Background Residual risk of cardiovascular disease from increased small dense low-density lipoprotein (sdLDL)-cholesterol levels and low n-3 polyunsaturated fatty acid (PUFA) levels is a considerable therapeutic issue. The purpose of this study was to evaluate the effect of ezetimibe as an add-on to statins and supplemental eicosapentaenoic acid (EPA) on sdLDL cholesterol and absorption of EPA in patients with coronary artery disease. Methods The study population consisted of ten male patients who were concurrently receiving statins and EPA 1,800 mg/day. Serum lipids and PUFAs, including EPA and arachidonic acid, were measured in blood samples collected before ezetimibe (baseline), 4 weeks after starting 10-mg/day ezetimibe, and 4 weeks after discontinuing ezetimibe. Results Ezetimibe significantly decreased sdLDL-cholesterol levels after 4 weeks of treatment (baseline 35 ± 13 mg/dl; treatment 27 ± 9 mg/dl), but the levels returned to baseline after discontinuation of ezetimibe (37 ± 13 mg/dl). The concentration of EPA did not significantly change during the study.
Introduction
Decreasing low-density lipoprotein (LDL)-cholesterol levels is the primary goal in the management of dyslipidemia in patients at high risk of cardiovascular disease [1] [2] [3] . Despite the use of statins which enable the achievement of targeted LDL-cholesterol levels, a substantial number of coronary events still occur [4, 5] , which may result, in part, from elevated levels of triglycerides and triglyceride-rich lipoprotein remnants, and low levels of high-density lipoprotein (HDL) cholesterol, which are often accompanied by high levels of small dense LDL (sdLDL) cholesterol. This combination is referred to as atherogenic dyslipidemia [6] , which is highly prevalent in patients with diabetes mellitus or metabolic syndrome. In the Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (INTERHEART) study, the risk associated with atherogenic dyslipidemia was shown to be independent to LDL-cholesterol levels [7] . To reduce the risk of coronary artery disease (CAD) further, secondary therapies to increase HDL cholesterol, decrease triglycerides and triglyceride-rich lipoprotein remnants, and lower sdLDL-cholesterol levels may be recommended for patients who achieve LDL-cholesterol levels below the currently recommended targets.
Ezetimibe, a cholesterol-absorption inhibitor, is used as an alternative to statins and as an add-on therapy for the reduction of LDL-cholesterol levels [8] [9] [10] . Ezetimibe decreases sdLDL-cholesterol levels when used in combination with statins [11, 12] , whereas eicosapentaenoic acid (EPA), an n-3 polyunsaturated fatty acid (PUFA), has been shown to lower sdLDL-cholesterol levels, alone or in combination with statins [13, 14] . Thus, combined treatment with a statin, ezetimibe, and EPA may have the potential to lower triglycerides and sdLDL-cholesterol levels in patients with atherogenic dyslipidemia. However, the effects of this triple therapy on sdLDL-cholesterol levels have not been fully elucidated. In addition, a previous animal study showed that ezetimibe significantly reduced absorption of dietary saturated fatty acids, but only a small effect was observed for the unsaturated fatty acids [15] . In humans, the effect of ezetimibe on absorption of EPA remains unclear.
The aim of this study was to evaluate if ezetimibe, as an add-on therapy to statin and EPA therapy, could lower sdLDL-cholesterol levels in patients with CAD, and if addon ezetimibe affects the absorption of supplemental EPA.
Methods

Participants and Design
This study was approved by the Ethics Committee of Okayama University Hospital and Tamashima Central Hospital, and written informed consent was obtained from all participants before beginning the protocol. This study was conducted according to the principles expressed in the Declaration of Helsinki. The study is registered on the UMIN Clinical Trials Registry (UMIN000012589). The schema of the study design is shown in Fig. 1 .
This prospective study consisted of ten outpatients with CAD who visited Tamashima Central Hospital (Okayama, Japan) regularly from May 2013 to November 2013. All enrolled patients had been receiving a statin and EPA (1,800 mg/day) for dyslipidemia and secondary prevention of CAD for [3 months. Patients were excluded from the study if they had experienced acute coronary syndromes, stroke, or heart failure; had undergone major surgery \3 months before enrollment; or had variant angina, concomitant inflammatory diseases, or malignant tumors. Hypertension was defined as a seated blood pressure C140/ 90 mmHg or current use of antihypertensive agents. Diabetes was defined as fasting blood glucose C126 mg/dl and hemoglobin A1c C 6.5 %, or as requiring antidiabetic agents. Dyslipidemia was diagnosed according to the 2012 Japan Atherosclerotic Society guidelines or as concurrent treatment with a cholesterol-lowering agent [16] . The prespecified primary outcome measure was the difference in sdLDL cholesterol after ezetimibe treatment, and the secondary outcome measure was the difference in n-3 PUFAs after ezetimibe treatment. Blood samples were collected prior to ezetimibe administration (baseline), 4 weeks after starting ezetimibe, and 4 weeks after discontinuation of ezetimibe.
Blood Examination
Venous blood samples were obtained from the patients when they visited the outpatient clinic after overnight fasting for 8-12 h. Serum lipids (total cholesterol, HDL cholesterol, and triglycerides) were measured using an autoanalyzer and routine methods at the central laboratory of Tamashima Central Hospital. LDL-cholesterol levels were calculated using Friedewald's equation [17, 18] . The serum levels of fatty acids and sdLDL cholesterol in fasting blood samples were analyzed at SRL Company Ltd. (Tokyo, Japan). In brief, for measuring fatty acids, the lipid fraction was extracted from serum into chloroform/methanol using Folch's procedure, and then fatty acids (tricosanoic acid, C23:0, as the internal standard) were methylated with boron trifluoride and methanol. The methylated fatty acids were then analyzed using a capillary gas chromatograph (GC-2010; Shimadzu, Kyoto, Japan) and a BPX70 capillary column (0.25-mm internal diameter 9 30 m; SGE International Ltd., Melbourne, Australia). We measured n-3 PUFA, including EPA and docosahexaenoic acid (DHA), and n-6 PUFA, including arachidonic acid (AA) and Fig. 1 Schema of the study design. EPA eicosapentaenoic acid, w weeks dihomo-c-linolenic acid (DGLA). sdLDL-cholesterol was measured using a commercially available assay kit (sdLDL-EX; Denka Seiken Co., Tokyo, Japan), as previously described [19] .
Statistical Analysis
Continuous variables are expressed as the mean ± standard deviation. Categorical variables are expressed as the number and percentage. Differences among the three time points were compared by repeated measures analysis of variance (ANOVA), with covariates including age, gender, current smoking, hypertension, and diabetes mellitus, and then followed by the Bonferroni post hoc test. A value of p \ 0.05 was considered significant. Calculations were performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
The baseline characteristics of the study participants are shown in Table 1 . The ten participants were all men (mean age 70 years). The statins used were pravastatin [two patients (10 mg/day)], atorvastatin [six patients (10 mg/ day)], and rosuvastatin [two patients (2.5 mg/day)]. Patients with diabetes mellitus accounted for 40 %. All patients maintained their body mass index during this study (at baseline 26.1 ± 4.9 kg/m 2 ; at 4 weeks after treatment 26.2 ± 5.6 kg/m 2 , and at 4 weeks after discontinuation 26.2 ± 5.2 kg/m 2 ). Changes in serum lipids and PUFAs in the ten patients are shown in Table 2 and Fig. 2 . Ezetimibe treatment for 4 weeks significantly decreased the concentrations of total cholesterol, LDL cholesterol, and sdLDL cholesterol (Fig 2a) , which returned to near baseline levels at 4 weeks after discontinuation of ezetimibe. The concentration of triglyceride tended to reduce for 4 weeks of ezetimibe treatment and returned to near baseline levels at 4 weeks after discontinuation of ezetimibe. Ezetimibe, however, did not significantly affect HDL-cholesterol, EPA (Fig. 2b) , DHA, DGLA, or AA levels during the study period (Table 2) . Consequently, ezetimibe did not affect the ratio of EPA to AA. Hemoglobin A1c, serum creatine, and creatine kinase were also did not change during this study (Table 2 ). There were no significant changes in systolic blood pressure and diastolic blood pressure during this study period (systolic pressure/diastolic pressure at baseline 125 ± 13/67 ± 8 mmHg, at 4 weeks after treatment 126 ± 14/70 ± 8 mmHg, and at 4 weeks after discontinuation 124 ± 13/71 ± 9 mmHg). No clinical or laboratory adverse events or discontinuation occurred during the study period.
Discussion
This study demonstrated that ezetimibe in addition to statins and EPA significantly decreased sdLDL-cholesterol levels, but did not affect the absorption of supplemental EPA in patients with CAD. For secondary prevention of CAD, ezetimibe in addition to statins and EPA may be useful for controlling residual risks.
Although the patients in this study achieved considerable reduction in LDL-cholesterol levels (\100 mg/dl) with a statin and supplemental EPA, we found that ezetimibe successfully reduced LDL-cholesterol levels even further. The fact that sdLDL-cholesterol levels returned to baseline values after discontinuation of ezetimibe clearly shows the effect of ezetimibe on lowering sdLDL-cholesterol levels. This finding was consistent with previous studies that ezetimibe alone or in combination with a statin lowered sdLDL-cholesterol levels in patients with diabetes and glucose intolerance [11, 12] . In contrast, a recent study showed that treatment with ezetimibe alone or in combination with a statin increases sdLDL cholesterol in healthy individuals [20] . This data suggested that ezetimibe was associated with the development of a pro-atherogenic LDL subfraction profile in subjects with a normal metabolic condition. The effect of ezetimibe on sdLDL cholesterol is still argued, because of the lack of clinical evidence of ezetimibe in cardiovascular events despite its significant LDL-cholesterol lowering effect; however, a larger study is warranted to evaluate the effect of ezetimibe on sdLDL cholesterol in patients with hypercholesterolemia or hypertriglyceridemia. Furthermore, our study demonstrates that ezetimibe decreases hypertriglyceridemia in patients receiving a statin and supplemental EPA, which is consistent with our previous findings that co-administration of ezetimibe and a statin reduce triglyceride levels in CAD patients [8] . Thus, ezetimibe in combination with a statin and EPA may be useful for reduction of residual risks, especially for secondary prevention of CAD. We also demonstrated that ezetimibe did not affect serum n-3 PUFA concentrations in patients receiving supplemental EPA. The mammalian cholesterol-transport protein Niemann-Pick C1-like 1 is located on the surface of enterocytes [21] . In mice, ezetimibe treatment or lack of Niemann-Pick C1-like 1 significantly reduces absorption of dietary saturated fatty acids, particularly stearate and palmitate, but has only a small effect on absorption of the unsaturated fatty acids oleate and linoleate [15] . These results are consistent with the effects of ezetimibe on the PUFAs that we measured. Conversely, Kurisu et al. [22] recently reported that strong statins reduce serum n-3 PUFA concentrations in proportion to the attendant decrease in LDL-cholesterol levels. This difference on absorption of n-3 PUFAs by statins and ezetimibe is clinically interesting. These results suggest that ezetimibe may be a preferred therapy for patients with atherogenic dyslipidemia; however, further investigation is needed to determine the optimal combination of therapies that will lower sdLDL-cholesterol levels in the absence of undesired side effects such as a decrease in n-3 PUFA levels. Previous studies suggested potential beneficial effects of n-3 PUFAs on cardiovascular disease [23] [24] [25] , while recent cardiovascular outcome studies on n-3 PUFA therapy have been disappointing [26] [27] [28] . One possible reason for this discrepancy was the dose of n-3 PUFA. Harris and Von Schacky [29] reported that greater fatty acid composition in red blood cell membranes was associated with greater cardioprotection; however, the 2013 AHA/ACC Cardiovascular Risk Reduction Guideline does not recommend strongly the supplemental use of n-3 PUFA [30] . Further studies are needed to assess n-3 PUFA therapies in the context of clinical care, using larger patient populations and larger doses; a number of epidemiologic studies have shown that a low n-3 PUFA level is a risk for CAD [31] [32] [33] . Thus, inhibition of absorption of n-3 PUFA is not favorable; therefore, our finding that ezetimibe did not affect EPA level may be informative.
Limitations to our study include the following. (1) This was an open-label add-on study. Evaluation at 4 weeks after discontinuation of ezetimibe and careful statistical analyses may have compensated for this limitation; however, there is no doubt that a larger study, preferably with a double-blind crossover, multicenter design, will be required to confirm our findings. (2) We measured the concentrations of EPA, DHA, DGLA, and AA, but did not evaluate their proportions relative to total free fatty acids. (3) This study included only a small number of patients with CAD on a particular combination treatment regimen, making it difficult to generalize the results to other populations.
Conclusions
Ezetimibe in addition to statins and EPA significantly decreased sdLDL-cholesterol, but did not affect serum EPA concentrations in patients with CAD. Ezetimibe may be a promising agent as an add-on therapy to statins and EPA to reduce residual risks in patients with CAD.
